Multidrug resistant tuberculosis-its extent, hazard and possible solutions;La tuberculose multirésistante: extension, menace et solutions

Revue des Maladies Respiratoires

Volumn 28, Issue 8, 2011, Pages 1025-1033

  Zellweger, J P ^a  

^a Centre de Compétence Tuberculose   (Switzerland)

Author keywords

MDR TB; Multidrug resistant tuberculosis; Treatment; Tuberculosis; XDR TB

Indexed keywords

ARTICLE; BACTERIAL STRAIN; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENETIC PROCEDURES; HAZARD; MULTIDRUG RESISTANT TUBERCULOSIS;

EID: 84155162969     PISSN: 07618425     EISSN: 17762588     Source Type: Journal    
DOI: 10.1016/j.rmr.2010.10.040     Document Type: Review

References (52)

1. British Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. A Medical Research Council investigation. BMJ 1948;2:769-83.
2. Caminero JA. Likelihood of generating MDR-TB and XDRTB under adequate National Tuberculosis Control Programme implementation. Int J Tuberc Lung Dis 2008;12:869-77.
3. Kimerling ME, Kluge H, Vezhnina N, et al. Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDR-TB. Int J Tuberc Lung Dis 1999;3:451-3. (Pubitemid 29294697)
4. Lew W, Pai M, Oxlade O, et al. Initial drug resistance and tuberculosis treatment outcomes: systematic review and metaanalysis. Ann Intern Med 2008;149:123-34. (Pubitemid 352008599)
5. Burgos M, DeRiemer K, Small PM, et al. Effect of drug resistance on the generation of secondary cases of tuberculosis. J Infect Dis 2003;188:1878-84. (Pubitemid 38064874)
6. Caminero JA. Multidrug-resistant tuberculosis: epidemiology risk factors case finding. Tuberc Lung Dis Int J 2010;14:382-90.
7. Um SW, Lee SW, Kwon SY, et al. Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels. Int J Tuberc Lung Dis 2007;11:972-8. (Pubitemid 47425023)
8. Kimerling ME, Phillips P, Patterson P, et al. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest 1998;113:1178-83. (Pubitemid 28223801)
9. Calver AD, Falmer AA, Murray M, et al. Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa. Emerg Infect Dis 2010;16:264-71.
10. Borrell S, Gagneux S. Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009;13:1456-66.
11. Aziz MA, Wright A. The World Health Organization/International Union Against Tuberculosis and Lung Disease Global Project on Surveillance for Anti-Tuberculosis Drug Resistance: a model for other infectious diseases. Clin Infect Dis 2005;41:S258-62.
12. Zignol M, Hosseini MS, Wright A, et al. Global incidence of multidrug-resistant tuberculosis. J Infect Dis 2006;194:479-85. (Pubitemid 44162659)
13. Wright A, Zignol M, Van DA, et al. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 2009;373:1861-73.
14. World Health Organization. Multidrug and extensively drugresistant TB.(M/XDR-TB). 2010 global report on surveillance and response. Geneva: 2010WHO/HTM/TB/2010.3.
15. Migliori GB, Centis R, Lange C, et al. Emerging epidemic of drug-resistant tuberculosis in Europe, Russia, China, South America and Asia: current status and global perspectives. Curr Opin Pulm Med 2010;16:171-9.
16. Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax 2006;61:158-63. (Pubitemid 43235434)
17. Helbling P, Altpeter E, Raeber PA, et al. Surveillance of antituberculosis drug resistance in Switzerland 1995-1997: the central link. Eur Respir J 2000;16:200-2. (Pubitemid 30624935)
18. Van DA, Martin A, Palomino JC. Diagnosis of drug-resistant tuberculosis: reliability and rapidity of detection. Int J Tuberc Lung Dis 2010;14:131-40.
19. Helb D, Jones M, Story E, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 2010;48: 229-37.
20. Balabanova Y, Drobniewski F, Nikolayevskyy V, et al. An integrated approach to rapid diagnosis of tuberculosis and multidrug resistance using liquid culture and molecular methods in Russia. PLoS ONE 2009;4:e7129.
21. Boehme CC, et al. Rapid molecular detection of tuberculosis and rifampin resistance. New Engl J Med 2010;363:1005-15.
22. World Health Organization. Treatment of tuberculosis. Guidelines. 4th ed. Geneva: World Health Organization, 2010WHO/HTM/TB/2009.420.
23. Goble M, Iseman MD, Madsen LA, et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993;328:527-32. (Pubitemid 23053828)
24. Iseman MD, Madsen L, Goble M, et al. Surgical intervention in the treatment of pulmonary disease caused by drugresistant mycobacterium tuberculosis. Am Rev Resp Child 1990;141:623-5. (Pubitemid 20109149)
25. Furin J. The clinical management of drug-resistant tuberculosis. Curr Opin Pulm Med 2007;13:212-7. (Pubitemid 46597625)
26. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. Geneva: 2008WHO/HTM/TB/2008. 402.
27. Van Deun A, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Resp Crit Care Med 2010;182:684-92.
28. Dartois V, Barry CE. Clinical pharmacology and lesion penetrating properties of second-and third-line antituberculous agents used in the management of Multidrug-Resistant (MDR) and Extensively-Drug Resistant (XDR) Tuberculosis. Curr Clin Pharmacol 2010;5:96-114.
29. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009;9:153-61.
30. World Health Organization. Global Tuberculosis Control 2009. Epidemiology, strategy, financing. Geneva: WHO, 2009WHO/HTM/TB/2009.411.
31. Kliiman K, Altraja A. Predictors and mortality associated with treatment default in pulmonary tuberculosis. Int J Tuberc Lung Dis 2010;14:454-63.
32. Laserson KF, Thorpe LE, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrugresistant tuberculosis. Int J Tuberc Lung Dis 2005;9:640-5. (Pubitemid 40826156)
33. Torun T, Gungor G, Ozmen I, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005;9:1373-7. (Pubitemid 43265148)
34. Bloss E, Kuksa L, Holtz TH, et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004. Int J Tuberc Lung Dis 2010;14:275-81.
35. Migliori GB, Eker B, Richardson MD, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in MDR-TB. Eur Respir J 2009;34:387-93.
36. Schecter GF, Scott C, True L, et al. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2010;50:49-55.
37. Hugonnet JE, Tremblay LW, Boshoff HI, et al. Meropenemclavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 2009;323:1215-8.
38. Katiyar SK, Bihari S, Prakash S, et al. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrugresistant tuberculosis. Int J Tuberc Lung Dis 2008;12:139-45. (Pubitemid 351212404)
39. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009;360:2397-405.
40. O'Brien RJ, Spigelman M. New drugs for tuberculosis: current status and future prospects. Clin Chest Med 2005;26:327-40, vii.
41. Spigelman M, Woosley R, Gheuens J. New initiative speeds tuberculosis drug development: novel drug regimens become possible in years, not decades. Int J Tuberc Lung Dis 2010;14:663-4.
42. Somocurcio JG, Sotomayor A, Shin S, et al. Surgery for patients with drug-resistant tuberculosis: report of 121 cases receiving community-based treatment in Lima, Peru. Thorax 2007;62:416-21. (Pubitemid 46698391)
43. Ormerod LP. Role of surgery in pulmonary multidrug-resistant tuberculosis. Thorax 2007;62:377. (Pubitemid 46698380)
44. Cain KP, Nelson LJ, Cegielski JP. Global policies and practices for managing persons exposed to multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2010;14:269-74.
45. Schaaf HS, Gie RP, Kennedy M, et al. Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics 2002;109:765-71. (Pubitemid 34493340)
46. Blower SM, Chou T. Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance. Nat Med 2004;10:1111-6. (Pubitemid 39424873)
47. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006;368:1575-80. (Pubitemid 44780738)
48. Shin SS, Keshavjee S, Gelmanova IY, et al. Development of extensively drug-resistant tuberculosis during multidrugresistant tuberculosis treatment. Am J Respir Crit Care Med 2010;182:426-32.
49. Velayati AA, Masjedi MR, Farnia P, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 2009;136:420-5.
50. Veen J. Drug resistant tuberculosis: back to sanatoria, surgery and cod-liver oil? Eur Respir J 1995;8:1073-5.
51. Dye C. Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. Nat Rev Microbiol 2009;7:81-7.
52. Chiang CY, Schaaf HS. Management of drug-resistant tuberculosis. Int J Tuberc Lung Dis 2010;14:672-82.